We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Timber Pharmaceuticals Inc | AMEX:TMBR | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3426 | 0 | 01:00:00 |
Details of the e-poster presentations at the 31st EADV Congress are as follows:
Poster Presentations
Title: Characteristics of patients with congenital ichthyosis achieving greater than 50% reduction in Visual Index for Ichthyosis Severity scaling score relative to baseline after topical isotretinoin formulation TMB-001: CONTROL study resultsPresenting Author: Christopher G. Bunick, MD, PhD, Yale University School of MedicinePoster Number: P1003
Title: Change in quality-of-life measurements after treatment with topical isotretinoin formulation (TMB-001) at 12 weeks in patients with congenital ichthyosis at baseline: Phase 2b CONTROL study resultsPresenting Author: Leslie Castelo-Soccio, MD, PhD, Perelman School of Medicine, University of Pennsylvania and Children’s Hospital of PhiladelphiaPoster Number: P1004
Title: Effect of topical isotretinoin formulation (TMB-001) concentration on incidence of local skin reactions in patients with congenital ichthyosis: Phase 2b CONTROL study resultsPresenting Author: Joyce M. C. Teng, MD, PhD, School of Medicine, Stanford UniversityPoster Number: P1005
Title: Effect of topical isotretinoin (TMB-001) treatment on laboratory parameters in patients with congenital ichthyosis: CONTROL study resultsPresenting Author: Alan M. Mendelsohn, MD, Timber PharmaceuticalsPoster Number: P1006
Title: Efficacy and safety of topical isotretinoin (TMB-001) treatment in patients with X-linked recessive or autosomal recessive lamellar congenital ichthyosis: CONTROL study resultsPresenting Author: Joyce M. C. Teng, MD, PhD, School of Medicine, Stanford UniversityPoster Number: P1007
Title: Efficacy of topical isotretinoin TMB-001 in children and adults with congenital ichthyosis: Phase 2b CONTROL study resultsPresenting Author: Joyce M. C. Teng, MD, PhD, School of Medicine, Stanford UniversityPoster Number: P1008
Title: Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the Phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosisPresenting Author: Dédée F. Murrell, MA, BMBCh, FAAD, MD, FACD, School of Medicine, University of New South WalesPoster Number: P1009
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI) and other sclerotic skin diseases. For more information, visit www.timberpharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc. John Koconis Chairman and Chief Executive Officerjkoconis@timberpharma.com
Investor Relations:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com
Media Relations: Adam DaleyBerry & Company Public Relations (212) 253-8881adaley@berrypr.com
1 Year Timber Pharmaceuticals Chart |
1 Month Timber Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions